Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

Back to Search
Print
Bookmark Trial

NCT03850483

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Anaheim Clinical Trials LLC-Clinical Research
Anaheim, California, 92801, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- plaque psoriasis for 6 months

- PGA score mild or moderate

- body surface area (BSA) 2-15%

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- other skin conditions that would interfere with the evaluation of psoriasis


- history of herpes zoster or simplex


- Infected with Mycobacterium tuberculosis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

PsoriasisStudy Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept
NCT00992394
  1. Besancon,
  2. Limoges,
  3. Lyon Cedex 03,
  4. Nantes Cedex 01,
  5. Nice Cedex 03,
  6. Paris,
  7. Pierre Benite,
  8. Poitiers,
  9. Reims,
  10. Toulouse Cedex,
  11. Berlin,
  12. Bochum,
  13. Erlangen,
  14. Frankfurt am Main,
  15. Freiburg,
  16. Hamburg,
  17. Osnabrueck,
  18. Athens,
  19. Thessaloniki,
  20. Budapest,
  21. Debrecen,
  22. Miskolc,
  23. Szeged,
  24. Catania,
  25. Chieti,
  26. Parma,
  27. Santander, Cantabria
  28. Alcorcon, Madrid
  29. Getafe, Madrid
  30. Alicante,
  31. Madrid,
  32. Malaga,
  33. Istanbul, Capa
  34. Ankara, Etlik
  35. Ankara, Etlik
  36. Ankara, Etlik
  37. Istanbul, Fatih
  38. Bursa, Gorukle
  39. Pendik, Istanbul
  40. Ankara, Sihhiye
  41. Ankara, Sihhiye
  42. Ankara,
  43. Bornova / Izmir,
  44. Abu Dhabi, UAE
  45. Harrogate,
  46. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisEffectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00678210
  1. Tucson, Arizona
  2. Little Rock, Arkansas
  3. Oceanside, California
  4. Jacksonville, Florida
  5. Miami, Florida
  6. West Dundee, Illinois
  7. Boston, Massachusetts
  8. Boston, Massachusetts
  9. Worcester, Massachusetts
  10. Saint Louis, Missouri
  11. East Windsor, New Jersey
  12. Paramus, New Jersey
  13. New York, New York
  14. Rochester, New York
  15. Winston Salem, North Carolina
  16. Cleveland, Ohio
  17. Norman, Oklahoma
  18. Lake Oswego, Oregon
  19. Portland, Oregon
  20. Portland, Oregon
  21. Philadelphia, Pennsylvania
  22. Greer, South Carolina
  23. Greer, South Carolina
  24. Mt. Pleasant, South Carolina
  25. Dallas, Texas
  26. Houston, Texas
  27. Webster, Texas
  28. Salt Lake City, Utah
  29. Norfolk, Virginia
  30. Vancouver, British Columbia
  31. Moncton, New Brunswick
  32. St. John's, Newfoundland and Labrador
  33. Halifax, Nova Scotia
  34. Halifax, Nova Scotia
  35. Halifax, Nova Scotia
  36. Barrie, Ontario
  37. London, Ontario
  38. North Bay, Ontario
  39. Waterloo, Ontario
  40. Windsor, Ontario
  41. Laval, Quebec
  42. Montreal, Quebec
  43. Montreal, Quebec
  44. Quebec,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisTopical CP-690,550 For Chronic Plaque Psoriasis
NCT00678561
  1. Irvine, California
  2. San Diego, California
  3. Chicago, Illinois
  4. Boston, Massachusetts
  5. Ann Arbor, Michigan
  6. Fridley, Minnesota
  7. Saint Louis, Missouri
  8. High Point, North Carolina
  9. WinstoN Salem, North Carolina
  10. Portland, Oregon
  11. Portland, Oregon
  12. Austin, Texas
  13. Salt Lake City, Utah
  14. Surrey, British Columbia
  15. St. John's, Newfoundland and Labrador
  16. Waterloo, Ontario
  17. Montreal, Quebec
  18. Montreal, Quebec
  19. Quebec,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisA One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
NCT01276639
  1. Birmingham, Alabama
  2. Irvine, California
  3. San Diego, California
  4. Santa Monica, California
  5. Denver, Colorado
  6. New Haven, Connecticut
  7. Ocala, Florida
  8. Tampa, Florida
  9. Alpharetta, Georgia
  10. Atlanta, Georgia
  11. Newnan, Georgia
  12. Springfield, Illinois
  13. Indianapolis, Indiana
  14. Boston, Massachusetts
  15. Boston, Massachusetts
  16. Omaha, Nebraska
  17. New York, New York
  18. Rochester, New York
  19. Raleigh, North Carolina
  20. Raleigh, North Carolina
  21. Norman, Oklahoma
  22. Lake Oswego, Oregon
  23. Pittsburgh, Pennsylvania
  24. Johnston, Rhode Island
  25. Knoxville, Tennessee
  26. Dallas, Texas
  27. Dallas, Texas
  28. Houston, Texas
  29. Spokane, Washington
  30. Spokane, Washington
  31. Wenatchee, Washington
  32. Madison, Wisconsin
  33. Winnipeg, Manitoba
  34. St. John's, Newfoundland and Labrador
  35. Halifax, Nova Scotia
  36. Barrie, Ontario
  37. Markham, Ontario
  38. North Bay, Ontario
  39. Oakville, Ontario
  40. Ottawa, Ontario
  41. Waterloo, Ontario
  42. Quebec,
  43. Barranquilla, Atlantico
  44. Bogot, Cundinamarca
  45. Berlin,
  46. Berlin,
  47. Bonn,
  48. Dresden,
  49. Hamburg,
  50. Kiel,
  51. Muenster,
  52. Schwerin,
  53. Vechta,
  54. Wuppertal,
  55. Kecskemet,
  56. Nyiregyhaza,
  57. Pecs,
  58. Maebashi-shi, Gunma
  59. Sapporo, Hokkaido
  60. Chuo-ku, Kobe
  61. Kumamoto-shi, Kumamoto
  62. Shinjyuku-ku, Tokyo
  63. Monterrey, Nuevo Leon
  64. Poznan,
  65. Szczecin,
  66. Wroclaw,
  67. Wroclaw,
  68. Belgrade,
  69. Tainan,
  70. Taipei,
  71. Simferopol, Crimea
  72. Kharkiv,
  73. Kyiv,
  74. Ternopil,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
Official Title  ICMJE A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY TO ASSESS EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
Brief Summary This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and approximately 4 week follow up period. Approximately 240 participants are planned to be randomized into the study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Psoriasis
Intervention  ICMJE
  • Drug: PF-06700841
    PF-06700841 topical cream
  • Drug: Vehicle (Placebo)
    Vehicle topical cream
Study Arms  ICMJE
  • Placebo Comparator: Vehicle cream QD
    Vehicle cream applied once daily (QD)
    Intervention: Drug: Vehicle (Placebo)
  • Experimental: PF-06700841 0.1% cream QD
    PF-06700841 0.1% cream applied once daily (QD)
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 0.3% cream QD
    PF-06700841 0.3% cream applied once daily (QD)
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 1% cream QD
    PF-06700841 1% cream applied once daily (QD)
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 3% cream QD
    PF-06700841 3% cream applied once daily (QD)
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 0.3% cream BID
    PF-06700841 0.3% cream applied twice daily (BID)
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 1% cream BID
    PF-06700841 1% cream applied twice daily (BID)
    Intervention: Drug: PF-06700841
  • Placebo Comparator: Vehicle cream BID
    Vehicle cream applied twice daily (BID)
    Intervention: Drug: Vehicle (Placebo)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: June 17, 2020)		294
Original Estimated Enrollment  ICMJE
 (submitted: February 20, 2019)		240
Estimated Study Completion Date  ICMJE April 21, 2021
Estimated Primary Completion Date April 21, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • plaque psoriasis for 6 months
  • PGA score mild or moderate
  • body surface area (BSA) 2-15%

Exclusion Criteria:

  • other skin conditions that would interfere with the evaluation of psoriasis
  • history of herpes zoster or simplex
  • Infected with Mycobacterium tuberculosis
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Bulgaria,   Canada,   Denmark,   Germany,   Hungary,   Japan,   Latvia,   Poland,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03850483
Other Study ID Numbers  ICMJE B7931023
2018-003051-38 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP